11![FAC T S H E E T Understanding Multiple Sclerosis THIS FACT SHEET explains what multiple sclerosis is, what we know about its cause and who develops it. It describes diagnosis, types of MS, symptoms, treatment and discus FAC T S H E E T Understanding Multiple Sclerosis THIS FACT SHEET explains what multiple sclerosis is, what we know about its cause and who develops it. It describes diagnosis, types of MS, symptoms, treatment and discus](https://www.pdfsearch.io/img/a995ba7ffc0af369572705df351e312f.jpg) | Add to Reading ListSource URL: www.abistafftraining.infoLanguage: English - Date: 2014-08-01 09:22:25
|
---|
12![Cytokines / Immunosuppressants / Medicine / Autoimmune diseases / Treatment of multiple sclerosis / Natalizumab / Glatiramer acetate / Fingolimod / Interferon beta-1a / Immunology / Immune system / Multiple sclerosis Cytokines / Immunosuppressants / Medicine / Autoimmune diseases / Treatment of multiple sclerosis / Natalizumab / Glatiramer acetate / Fingolimod / Interferon beta-1a / Immunology / Immune system / Multiple sclerosis](/pdf-icon.png) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2015-04-22 23:39:46
|
---|
13![Living Well with MS Fact Sheet Treatment Options for MS There is no cure for multiple sclerosis (MS) at the moment, but there are a number of treatments available which may help. These divide into three groups: Living Well with MS Fact Sheet Treatment Options for MS There is no cure for multiple sclerosis (MS) at the moment, but there are a number of treatments available which may help. These divide into three groups:](https://www.pdfsearch.io/img/32343eb85a28f47c230bde0884345aac.jpg) | Add to Reading ListSource URL: d1qmnn0xkv8u83.cloudfront.netLanguage: English - Date: 2014-07-07 02:15:08
|
---|
14![Teva buying Auspex for $3.2 billion Teva buying Auspex for $3.2 billion](https://www.pdfsearch.io/img/a73030a4dee31a17e1c3724bf9b955e3.jpg) | Add to Reading ListSource URL: medicalxpress.comLanguage: English - Date: 2015-05-10 14:07:10
|
---|
15![Glatiramer Acetate (Glatiramer Acetate) INJECTION, SOLUTION [Sandoz Inc] - Glatiramer Acetate (Glatiramer Acetate) INJECTION, SOLUTION [Sandoz Inc] -](https://www.pdfsearch.io/img/f91d92fcc9e114bcd755c4ae75b9a8fb.jpg) | Add to Reading ListSource URL: www.glatopa.comLanguage: English - Date: 2014-06-02 14:56:30
|
---|
16![Monte Carlo simulation of the Spearman-Kaerber TCID50 Monte Carlo simulation of the Spearman-Kaerber TCID50](https://www.pdfsearch.io/img/afd666150f635b360c1e2d5b20a6b71b.jpg) | Add to Reading ListSource URL: www.jclinbioinformatics.comLanguage: English |
---|
17![Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx](https://www.pdfsearch.io/img/4cb39b7baa39105aac5c52d724e69293.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2015-04-22 23:39:46
|
---|
18![Mouse EAE Models Overview and Model Selection January Mouse EAE Models Overview and Model Selection January](https://www.pdfsearch.io/img/8dd02ccc6ddfb38b6bc1b36dc94d995f.jpg) | Add to Reading ListSource URL: hookelabs.comLanguage: English - Date: 2015-01-15 22:02:16
|
---|
19![Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and](https://www.pdfsearch.io/img/ae53c80da548361bf470505977c535cc.jpg) | Add to Reading ListSource URL: protectbenefitrisk.euLanguage: English - Date: 2014-07-16 01:09:14
|
---|
20![Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology.](https://www.pdfsearch.io/img/58e69404bf0a357077fa3068e3b084c3.jpg) | Add to Reading ListSource URL: protectbenefitrisk.euLanguage: English - Date: 2014-07-16 01:09:12
|
---|